Strong Q2 revenue growth of 55% year-over-year, raised full-year guidance, positive Phase 2 data for lead pipeline candidate KPL-387 supporting Phase 3 initiation, solid cash position of $525.9 million with no debt, and cash flow positive operations demonstrate strong commercial execution and clinical progress.
Company delivered a beat-and-raise quarter with revenue significantly exceeding expectations ($214M vs. $207M consensus), net income more than doubling, and management raising full-year guidance. The recent pericarditis approval for Arcalyst is driving strong sales growth, and the analyst views the company's prospects as bullish despite being a single-product company.
Articles that tag KNSA but are mainly about other companies.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
